These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 2145023)

  • 1. Three reports at ASCO show ondansetron to be a very effective antiemetic with few side effects.
    Oncology (Williston Park); 1990 Sep; 4(9):98, 102. PubMed ID: 2145023
    [No Abstract]   [Full Text] [Related]  

  • 2. Potent antiemetic effects of the new serotonin antagonists.
    Ryan KP; Evans JS
    West J Med; 1992 Jan; 156(1):67. PubMed ID: 1531161
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety of ondansetron.
    Smith RN
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S47-50; discussion S51-4. PubMed ID: 2533899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimes.
    Schmoll HJ
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S35-9. PubMed ID: 2533897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological and anti-emetic properties of ondansetron.
    Tyers MB; Bunce KT; Humphrey PP
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S15-9. PubMed ID: 2533894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ondansetron, important new antiemetic, approved by FDA.
    Oncology (Williston Park); 1991 Mar; 5(3):12. PubMed ID: 1829939
    [No Abstract]   [Full Text] [Related]  

  • 7. Nurses' perceptions of antiemetic effectiveness.
    Rhodes VA; McDaniel RW; Simms SG; Johnson M
    Oncol Nurs Forum; 1995 Sep; 22(8):1243-52. PubMed ID: 8532549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ondansetron: a new entity in emesis control.
    Graves T
    DICP; 1990 Nov; 24(11 Suppl):S51-4. PubMed ID: 2148659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Use of ondansetron, a 5-HT3 receptor antagonist, as a new type of antiemetic in pediatric oncology].
    Csáki C; Ferencz T; Koós R; Schuler D; Borsi J
    Orv Hetil; 1993 Jun; 134(25):1363-7. PubMed ID: 8332356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
    Slabý J; Trnený M; Procházka B; Klener P
    Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting.
    Marty M
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S41-5. PubMed ID: 2533898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proceedings of the Ondansetron Symposium. London, 30 June 1989.
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S1-93. PubMed ID: 2533893
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical studies with ondansetron in the control of radiation-induced emesis.
    Priestman TJ
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S29-33. PubMed ID: 2533896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of serotonin antagonists for the control of chemotherapy-induced emesis.
    Hainsworth JD
    Semin Surg Oncol; 1993; 9(3):279-84. PubMed ID: 8516617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New antiemetic effective for cisplatin-induced emesis.
    Oncology (Williston Park); 1989 Jul; 3(7):79. PubMed ID: 2534945
    [No Abstract]   [Full Text] [Related]  

  • 16. Preliminary experience with use of a selective 5HT3 receptor antagonist (ondansetron) to prevent high dose chemotherapy induced emesis.
    Parikh PM; Shah SR; Shah SC; Sheth V; Patel RA; Shah KC; Jain PK
    Indian J Cancer; 1996 Mar; 33(1):17-20. PubMed ID: 9063013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugs recently released in Belgium. Milrinone--ondansetron.
    Harvengt C
    Acta Clin Belg; 1991; 46(1):56-60. PubMed ID: 1645919
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-hydroxytryptamine-3 antagonists: a new class of potent antiemetics in cancer therapy.
    Soukop M
    Recent Results Cancer Res; 1991; 121():86-90. PubMed ID: 1650016
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmaceutical development of ondansetron injection.
    Leak RE; Woodford JD
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S67-9. PubMed ID: 2533902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.